Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPPBiotechnology
+$0.02 today
- Market cap
- $1.12B
- Beta
- 0.98
- P/E (TTM)
- -16.2
- EPS (TTM)
- -$2.27
Volume 0.73M
Average 0.33M
RAPP Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Rapport Therapeutics, Inc. Common StockNASDAQ: RAPP
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity rises 65.0% from a year ago
Total equity stood at $471.51M at the end of Q1 FY2026, up 65.0% from a year earlier and down 2.7% from the prior quarter. Over 3 fiscal years it compounded at +191.8% a year.
Context
- Total equity amounted to 94.8% of total assets at the end of Q1 FY2026, up 0.1 pp from a year earlier.
- Total equity increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +65.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 484.65M USD
- Year-over-year change
- +58.7%
- 3-year CAGR
- +191.8%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 484.65M | +58.7% |
| FY2024 | 2024-12-31 | 305.43M | +1291.5% |
| FY2023 | 2023-12-31 | (25.63M) | -231.4% |
| FY2022 | 2022-12-31 | 19.51M | — |
Total Equity vs competitors
How RAPP compares with its peers on the latest reported figures
- RAPP's Mar 2026 total equity of $471.51M is the 3rd highest of the 10 companies compared; the peer median is $250.04M.
- Its year-over-year change of +65.0% is the 6th highest of 10, against a peer median of +75.0%.
- Total equity amounts to 94.8% of total assets for RAPP, versus a peer median of 88.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $1.39B | +51.3% | +45.3% | 77.3% | |
| Sep 2026 | $1.26B | +266.7% | +126.0% | 96.0% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $471.51M | +65.0% | +191.8% | 94.8% |
| Mar 2026 | $399.83M | +330.0% | +180.0% | 95.5% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $378.69M | +3546.2% | — | 96.2% |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $250.04M | +35.3% | +88.0% | 95.7% |
| Mar 2026 | $243.37M | +75.0% | — | 88.1% | |
| Jun 2026 | $83.3M | +14.0% | -6.9% | 10.9% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $70.68M | -69.0% | — | 45.9% |
| Mar 2026 | $29.91M | +143.8% | -5.2% | 82.8% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding RAPP) | $250.04M | +75.0% | +66.6% | 88.1% | |
Competitors are the stored peer set for RAPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
Intrinsic Alpha fair value
Locked
Current Price
$23.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.